from what I've read, it's not really mRNA that gives Moderna any advantage, as much as being able to raise broadly-neutralizing antibodies (BNAbs) against HIV m

from what I've read, it's not really mRNA that gives Moderna any advantage, as much as being able to raise broadly-neutralizing antibodies (BNAbs) against HIV membrane protein. but.. it's still not a polyvalent vaccine, it's only targeting one such highly-conserved region, and there's HIV out there that evades BNAbs (5% of HIV+ patients have BNAbs after all, and they eventually progress.. though maybe after changing tropism or something.) so it may not be all that effective as a strategy, but there's at least some monkey data suggesting it delays or sometimes prevents infection. More info here: https://www.aidsmap.com/news/mar-2020/hiv-vaccine-generates-broadly-neutralising-antibodies-passes-first-safety-and-proof https://www.aidsmap.com/news/mar-2020/hiv-vaccine-generates-...